查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1981457

癌症治疗领域新型药物递送系统市场：按产品类型、药物类型、技术平台和应用划分－2026-2032年全球预测

NDDS in Cancer Therapy Market by Product Type, Drug Type, Technology Platform, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，用于癌症治疗的 NDDS 市场价值将达到 133.5 亿美元，到 2026 年将增长到 151.8 亿美元，到 2032 年将达到 329 亿美元，复合年增长率为 13.74%。

主要市场统计数据
基准年 2025 133.5亿美元
预计年份：2026年 151.8亿美元
预测年份 2032 329亿美元
复合年增长率 (%) 13.74%

全面概述了奈米载体和基于设备的跨学科平台创新如何重新定义肿瘤治疗策略和临床应用。

新一代药物递送系统（NDDS）正在重塑肿瘤治疗，实现更精准、高效且以患者为中心的介入。载体结构和製剂科学的进步使得药物动力学可控、肿瘤蓄积增强、标靶外毒性降低成为可能，拓宽了现有细胞毒性药物和新型生物製药的治疗指数。这些优势的实现得益于多种材料平台，包括基于树状聚合物聚合物的支架、仿生外泌体材料、脂质奈米载体、传统脂质体，甚至金属奈米颗粒结构、胶束、奈米乳液和聚合物奈米颗粒系统。每种平台都具有独特的理化性质，这些性质会影响药物量、稳定性、循环时间和组织渗透性。

这是技术、临床实践和製造领域的一个重要转折点，它全面重塑了癌症治疗中标靶递送和联合治疗的开发和商业化。

在技​​术融合、监管进步和临床范式转变的推动下，癌症治疗的药物传递领域正经历着变革性的转变。其中一个关键变化是主动标靶技术的成熟。配体介导和受体导向的策略已超越概念验证阶段，在特定适应症中展现出可重复的标靶结合和更佳的治疗窗口。同时，被动标靶策略也在不断发展，透过先进的颗粒工程和表面化学技术，延长药物循环半衰期并调控肿瘤渗透动力学。这些科学进步得益于有效载荷模式的同步发展，特别是将siRNA和寡核苷酸药物等核酸疗法与脂质和大分子载体相结合，实现了传统製剂无法实现的细胞内基因调控。

分析自 2025 年开始的关税政策的最新转变如何重塑了先进肿瘤治疗系统的供应链韧性、筹资策略和商业性考虑。

美国2025年实施的新关税措施为奈米药物分销系统（NDDS）生态系统带来了一系列营运和战略压力，影响了供应链、筹资策略和成本结构。即时的营运影响体现在对通常透过全球供应商采购的特殊原料和先进添加剂的采购上，例如某些脂质、特殊聚合物以及用于金属奈米颗粒的试剂级金属。随着企业适应原材料成本和前置作业时间的波动，采购团队优先考虑供应商多元化、选择替代供应商以及双边协议，包括对本地製造能力的共同投资。这些调整加速了关于供应本地化的讨论，并促使企业更加重视为关键零件和契约製造活动建构具有韧性的国内或近岸生产能力。

观点，主导了产品类别、有效载荷类别、临床应用和平台技术如何协调一致，从而确定策略发展重点。

明确细分市场对于理解新型药物递送系统（NDDS）整体情况下技术价值与临床应用机会的交会点至关重要。依产品类型进行分析可以清楚展现其价值提案。树状聚合物和聚合物奈米颗粒具有可调控的结构，能够实现精准的药物负载和可控释放。受外泌体启发的平台为免疫调节和细胞内转运提供了仿生界面。脂质奈米载体和脂质体因其良好的生物相容性和监管记录，仍然是核酸和小分子有效载荷的核心；金属奈米颗粒可透过造影和光热治疗等方式发挥诊断和治疗诊断学的作用；胶束和奈米乳液为溶解疏水性抗癌药物提供了低成本、可扩展的选择。每类产品都有其独特的开发路径和转化研究中的瓶颈，因此，开发优先顺序必须使平台特性与临床未满足的需求相符。

决定如何在三大全球市场区域协调临床开发、生产规模化和商业部署的区域趋势和策略要求。

区域趋势对非分散式数位服务 (NDDS) 的发展路径、合作伙伴选择和商业化策略有显着影响。在美洲，强大的创业投资生态系统、密集的生物技术丛集和活跃的临床试验环境为快速转化应用提供了支持。法律规范强调对新型疗法的早期介入和指导，并且拥有完善的专业合约开发和生产组织 (CDMO) 网络来支持规模化生产。这些因素共同创造了一个First-in-Class技术快速达成临床里程碑并吸引策略伙伴关係的环境。

典型的策略行动、伙伴关係和业务重点，定义了主要企业如何将其交付平台的优势转化为临床和商业性优势。

整个新型药物递送系统（NDDS）生态系统中的竞争行为呈现出垂直整合、专业化分工和策略联盟并存的态势。成熟的製药公司越来越多地寻求许可和选择性收购，以整合与其治疗产品线互补的递送技术；而专业的合约开发公司和技术主导则专注于平台成熟和监管示范点。目前存在一个明显的趋势，即透过Start-Ups将製剂技术诀窍和临床开发能力相结合，从而加快概念验证（PoC）并降低初始人体试验的风险。

为经营团队提供切实有效的策略建议，以加速先进癌症药物传输技术的研发，降低营运风险，并确保监管和商业优势。

新型药物递送系统（NDDS）领域的领导者必须采取切实可行的策略，平衡技术创新、商业性可行性和合理的监管应对措施。首先，应优先与监管机构进行早期且持续的合作，以明确可接受的终点指标、对照组策略和分析预期。这将减少后期阶段的意外事件，并加快研发进度。其次，应投资于模组化和扩充性的生产解决方案以及多供应商策略，以降低供应中断和关税相关波动风险。第三，应设计整合基于生物标记的患者选择和适应性试验设计的临床开发项目，以增强讯号检测并优化资源分配。第四，应寻求能够将製剂专业知识与临床开发能力结合的伙伴关係。这包括与在植入式和微针平台上拥有设备整合经验的团队合作。

结合专家访谈、技术成熟度评估和证据整合的稳健的跨学科研究途径，检验了转化和商业性结论。

本执行摘要所依据的研究整合了多种证据来源，以得出精炼且可操作的见解。主要资讯来源包括对生物技术公司、製药公司和合约服务机构 (CSO) 的製剂科学家、临床开发经理、生产主管和监管专家的结构化访谈。这些访谈探讨了技术挑战、商业化重点以及预期的开发策略转变。此外，研究还利用同行评审文献、临床试验註册数据、专利申请和已发布的监管指导文件，全面检验了平台性能、临床终点和核准途径的趋势。

将技术进步、临床策略和营运准备整合到一个机制中，以便协作确定哪些治疗技术创新将在未来对肿瘤医学产生有意义的变革。

肿瘤学领域新一代药物递送系统的最新进展预示着一个新时代的到来，在这个时代，递送技术的创新对于治疗效果、患者体验和商业性差异化至关重要。树状聚合物、脂质载体、外泌体衍生结构和植入式装置的工程技术进步，使得药物暴露在精确的时空控製成为可能；而核酸疗法和靶向生技药品的引入，则拓展了可靶向的分子通路范围。伴随这些技术进步，临床开发模式也在转变，更加强调基于生物标记的患者筛选以及整合免疫调节和局部递送的联合治疗策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：癌症治疗中的新药物递送系统市场：依产品类型划分

  • 树状聚合物
  • 外泌体
  • 脂质奈米载体
  • 脂质体
  • 金属奈米粒子
  • 米歇尔
  • 奈米乳液
  • 聚合物奈米粒子

第九章：以药物类型分類的癌症治疗领域新型药物递送系统市场

  • 基因治疗药物
  • 单株抗体
  • 寡核苷酸製剂
  • siRNA
  • 低分子量化疗药物

第十章：基于技术平台的癌症治疗新型药物递送系统市场

  • 植入式缓释系统
  • 悬浮液用悬浮液
  • 微针系统
  • 奈米科技

第十一章：癌症治疗中的新药物递送系统市场：按应用领域划分

  • 化疗
  • 免疫疗法
  • 动态疗法
  • 放射线治疗
  • 分子标靶治疗

第十二章：癌症治疗中的新药递送系统市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：癌症治疗中的新药物递送系统市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：癌症治疗中的新药物递送系统市场：按国家/地区划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国癌症治疗中的新型药物传递系统市场

第十六章：中国癌症治疗领域的新型药物递送系统市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Samyang Holdings Corporation
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • West Pharmaceutical Services, Inc.
Product Code: MRR-521BAA36EBB7

The NDDS in Cancer Therapy Market was valued at USD 13.35 billion in 2025 and is projected to grow to USD 15.18 billion in 2026, with a CAGR of 13.74%, reaching USD 32.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.35 billion
Estimated Year [2026] USD 15.18 billion
Forecast Year [2032] USD 32.90 billion
CAGR (%) 13.74%

Comprehensive overview of how multidisciplinary platform innovations in nanocarriers and device-based systems are redefining therapeutic strategies and clinical translation in oncology

Next-generation drug delivery systems (NDDS) are reshaping the therapeutic playbook for oncology by enabling more precise, effective, and patient-centric interventions. Advances in carrier architectures and formulation science have unlocked the ability to control pharmacokinetics, enhance tumor accumulation, and reduce off-target toxicities, thereby broadening the therapeutic index of both established cytotoxics and novel biologics. These capabilities are realized through a spectrum of material platforms that range from dendrimer-based scaffolds and exosome-inspired biomimetics to lipid nanocarriers and conventional liposomes, as well as metallic nanoparticle constructs, micelles, nanoemulsions, and polymeric nanoparticle systems. Each platform brings distinctive physicochemical attributes that influence payload loading, stability, circulation time, and tissue penetration.

Equally important is the breadth of cargo that modern NDDS can transport. The field now routinely incorporates gene therapy agents, monoclonal antibodies, oligonucleotide drugs, siRNA constructs, and small-molecule chemotherapeutics within engineered carriers, enabling combination regimens and multi-modal modes of action. These payloads map to clinical applications that include chemotherapy, immunotherapy, photodynamic therapy, radiotherapy, and targeted therapy, and they frequently require bespoke delivery considerations to reach intracellular or tumor microenvironment targets. Complementing material and payload innovation are emergent technology platforms such as implantable depot systems, injectable suspensions, microneedle systems, and nanotechnology-based constructs. Within nanotechnology, design choices emphasize either active targeting strategies, which use ligand-directed or receptor-mediated mechanisms to engage specific cell populations, or passive targeting approaches that exploit size, surface chemistry, and the enhanced permeability and retention effect to concentrate agents in tumor tissue.

This introduction frames a landscape in which engineering, biology, regulatory science, and clinical practice converge. Translational progress depends not only on demonstrating enhanced efficacy and safety in controlled studies, but also on solving downstream challenges in scalable manufacturing, reproducible characterization, and regulatory alignment. As a result, stakeholders from discovery scientists and formulation engineers to clinical operations and commercial teams must coordinate across increasingly multidisciplinary pathways to advance NDDS from concept to clinic.

Key technological, clinical, and manufacturing inflection points that collectively reconfigure how targeted delivery and combination regimens are developed and commercialized in cancer care

The landscape for oncology drug delivery is undergoing transformative shifts driven by technological convergence, regulatory evolution, and evolving clinical paradigms. A critical shift is the maturation of active targeting approaches; ligand-mediated and receptor-directed strategies are moving beyond proof-of-concept to demonstrate reproducible target engagement and improved therapeutic windows in selective indications. At the same time, passive targeting strategies have evolved through refined particle engineering and surface chemistries that extend circulation half-life and modulate tumor penetration kinetics. These scientific advances are accelerated by parallel progress in payload modalities, notably the integration of nucleic acid therapeutics such as siRNA and oligonucleotide drugs with lipid and polymeric carriers, enabling intracellular gene modulation previously unattainable with traditional formulations.

Another major shift is the growing prominence of combination regimens in which NDDS enable co-delivery of immunomodulators alongside cytotoxics or targeted agents to reshape the tumor microenvironment. Here, the coupling of formulation innovation to immunotherapy mechanisms has created new trial designs and regulatory considerations. Concurrently, advances in implantable depot systems and microneedle platforms are expanding access pathways for localized delivery, which can reduce systemic exposure and improve adherence. From a manufacturing and commercialization perspective, the industry is witnessing investments in modular and continuous production technologies to improve batch-to-batch consistency and scale while maintaining stringent controls on critical quality attributes. Finally, data-driven personalization, including biomarker-driven patient selection and companion diagnostics, is becoming a cornerstone of clinical development strategies, ensuring that delivery innovations are paired with patient populations most likely to benefit. Together, these shifts reposition drug delivery as a central enabler of next-generation oncology therapeutics rather than a peripheral formulation exercise.

Analysis of how recent tariff policy shifts initiated in 2025 have reshaped supply chain resilience, sourcing strategies, and commercial considerations for advanced oncology delivery systems

The implementation of new tariff measures in the United States in 2025 has introduced a set of operational and strategic pressures on the NDDS ecosystem, influencing supply chains, sourcing strategies, and cost structures. Immediate operational impacts were felt in the procurement of specialized raw materials and advanced excipients frequently sourced through global suppliers, including certain lipids, specialty polymers, and reagent-grade metals used in metallic nanoparticles. As companies adjusted to altered input costs and lead times, procurement teams prioritized supplier diversification, qualification of alternative suppliers, and bilateral agreements that include co-investment in local manufacturing capabilities. These adjustments have hastened conversations around regionalization of supply, with an intensified focus on building resilient domestic or nearshore capacity for critical components and contract manufacturing activities.

For R&D and clinical programs, the tariff-driven environment emphasized the value of flexible formulation approaches that reduce reliance on single-source inputs. Development teams accelerated the assessment of alternative chemistries and process routes to mitigate exposure to tariff volatility. In parallel, strategic alliances and licensing deals became more prevalent as firms sought to secure access to essential technologies and to share the financial burden of localized manufacturing investments. From a commercial standpoint, pricing strategies and contracting negotiations have had to account for potential margin compression while maintaining competitiveness in global markets. These dynamics also influenced regional deployment decisions; emerging plans to expand capacity in jurisdictions with preferential trade arrangements or established manufacturing ecosystems have gained traction. Ultimately, the tariff environment compelled organizations to balance near-term cost management with longer-term investments in supply chain robustness, regulatory alignment for new manufacturing sites, and targeted vertical integration to safeguard critical capabilities.

Insightful segmentation-driven perspective revealing how product classes, payload categories, clinical applications, and platform technologies align to inform strategic development priorities

Segmentation clarity is essential to understand where technological value and clinical opportunity intersect across the NDDS landscape. When dissected by product type, distinct value propositions emerge: dendrimers and polymeric nanoparticles offer tunable architectures for precise drug loading and controlled release; exosome-inspired platforms provide biomimetic interfaces for immune modulation and intracellular trafficking; lipid nanocarriers and liposomes remain central for nucleic acid and small-molecule payloads because of their biocompatibility and regulatory precedent; metallic nanoparticles enable diagnostic and theranostic roles through imaging contrast and photothermal modalities; micelles and nanoemulsions present low-cost, scalable options for solubilizing hydrophobic chemotherapeutics. Each class carries unique development pathways and translational bottlenecks, and development prioritization should align platform attributes with clinical unmet needs.

In terms of drug type, the integration of gene therapy agents and siRNA into delivery constructs necessitates high-performance encapsulation and endosomal escape solutions, while monoclonal antibodies and oligonucleotide drugs impose distinct stability and conjugation requirements. Small-molecule chemotherapeutics, conversely, often benefit from carriers that modulate pharmacokinetics to reduce systemic toxicity and enhance tumor exposure. Application-focused segmentation elucidates opportunity clusters: chemotherapy remains a dominant use case for improved safety and targeted exposure; immunotherapy benefits from delivery systems that modulate antigen presentation and immune cell trafficking; photodynamic and radiotherapy adjuncts gain from carriers that localize photosensitizers or radiosensitizers within tumor microenvironments; targeted therapy is increasingly paired with nanocarriers that enable intracellular delivery to otherwise inaccessible targets.

Evaluating technology platforms reveals implementation pathways and clinical adoption drivers. Implantable depot systems provide sustained local concentrations and are attractive for site-specific control in solid tumors. Injectable suspensions and microneedle systems support ambulatory care and enhanced patient adherence, reducing reliance on infusion centers. Within the broader nanotechnology domain, design trade-offs between passive and active targeting shape efficacy outcomes: passive targeting leverages colloidal stability and size to exploit tumor physiology, whereas active targeting uses ligand-directed or receptor-mediated mechanisms to enhance cell specificity. The hierarchical segmentation across product types, drug classes, applications, and platform technologies therefore guides investment prioritization and clinical translation strategies based on technical feasibility, regulatory precedent, and patient care models.

Regional dynamics and strategic imperatives that determine how clinical development, manufacturing scale-up, and commercial deployment should be tailored across three major global market spheres

Regional dynamics significantly influence development pathways, partner selection, and commercialization strategies for NDDS. In the Americas, strong venture capital ecosystems, dense biotech clusters, and an active clinical trial environment underpin rapid translational activity. The regulatory framework emphasizes early engagement and guidance for novel modalities, and there is substantial capacity in both specialized contract development and manufacturing organizations to support scale-up efforts. These factors create an environment where first-in-class technologies frequently reach clinical milestones and attract strategic partnerships.

Europe, the Middle East and Africa present a heterogeneous landscape in which advanced regulatory expertise and academic research centers drive scientific innovation, while market access and reimbursement frameworks can vary widely across jurisdictions. European innovators often benefit from collaborative networks and public-private partnerships that advance translational science, whereas emerging markets within the broader region may prioritize cost-effective and scalable delivery approaches that address access and infrastructure constraints.

Asia-Pacific is characterized by rapidly expanding manufacturing capacity, significant government-led investments in biotech infrastructure, and large patient populations that are attractive for clinical development and real-world evidence generation. Local champions in several markets have demonstrated strength in formulation development and high-throughput manufacturing, which supports global supply diversification strategies. Across these regions, differentiated commercialization pathways-ranging from premium, high-touch launch models in developed markets to pragmatic, cost-sensitive approaches in certain emerging markets-require adaptive strategies that align regulatory tactics, partnership models, and production footprints with regional access and reimbursement landscapes.

Strategic behaviors, partnership archetypes, and operational priorities that define how leading organizations convert delivery platform strengths into clinical and commercial advantage

Competitive behavior across the NDDS ecosystem reflects a mix of vertical integration, focused specialization, and strategic partnering. Established pharmaceutical companies increasingly pursue in-licensing and selective acquisitions to incorporate delivery expertise that complements therapeutic pipelines, while specialized contract developers and technology-focused start-ups concentrate on platform maturation and regulatory proof points. There is a clear trend toward alliances that combine formulation know-how with clinical development capabilities, enabling faster proof-of-concept and de-risking of first-in-human studies.

Key operational imperatives observed among leading organizations include investment in robust CMC development, rigorous characterization of critical quality attributes, and early alignment with regulators on comparability strategies for complex formulations. Companies that have advanced clinical-stage NDDS programs often invest in orthogonal analytical methods and process controls that reduce variability and facilitate scale-up. Intellectual property strategies commonly balance core composition-of-matter protections with targeted method and use patents, while freedom-to-operate assessments guide partnership and licensing negotiations. In addition, cross-sector collaborations with diagnostics and biomarker providers are shaping companion diagnostic strategies that link delivery innovations to patient selection criteria. Collectively, these behaviors underscore the importance of integrated technical, regulatory, and commercial planning to translate platform advantage into sustainable market adoption.

Practical and high-impact strategic recommendations for executive teams to accelerate development, mitigate operational risks, and secure regulatory and commercial advantage in advanced oncology delivery

Leaders in the NDDS space must adopt actionable strategies that align technical innovation with commercial viability and regulatory pragmatism. First, prioritize early and continuous regulatory engagement to define acceptable endpoints, comparator strategies, and analytical expectations; this reduces late-stage surprises and accelerates development timelines. Second, invest in modular, scalable manufacturing solutions and multi-sourcing strategies that reduce exposure to supply disruptions and tariff-related volatility. Third, design clinical development programs that integrate biomarker-driven patient selection and adaptive trial designs to enhance signal detection and optimize resource allocation. Fourth, pursue partnerships that pair formulation expertise with clinical development capabilities, including alliances with groups experienced in device integration for implantable and microneedle-based platforms.

Fifth, align portfolio decisions with differentiated value propositions, focusing resources on platform-payload combinations likely to demonstrate clinically meaningful improvements in therapeutic index or patient experience. Sixth, strengthen intellectual property and data exclusivity strategies that cover both composition and manufacturing innovations, and consider defensive filings where platform modularity might invite competition. Seventh, embed real-world evidence and health economics planning into development to support payer discussions and reimbursement models. Finally, cultivate multidisciplinary teams that bridge materials science, translational biology, regulatory affairs, and commercial strategy to ensure that technical advances are translated into viable therapeutic solutions and sustainable business models.

Robust and multidisciplinary research approach combining expert interviews, technology readiness assessments, and evidence synthesis to validate translational and commercial conclusions

The research underpinning this executive summary integrates multiple evidence streams to generate nuanced, action-oriented insights. Primary inputs included structured interviews with formulation scientists, clinical development leads, manufacturing executives, and regulatory specialists across biotech, pharmaceutical, and contract service organizations. These conversations explored technical challenges, commercialization priorities, and anticipated shifts in development strategies. Secondary research drew on peer-reviewed literature, clinical trial registries, patent filings, and public regulatory guidance documents to triangulate trends in platform performance, clinical endpoints, and approval pathways.

Analytical methods combined qualitative synthesis with technology readiness assessments that evaluated translational hurdles such as encapsulation efficiency, stability, and manufacturability. Supply chain and policy impacts were examined through scenario analysis that considered raw material sourcing, regional manufacturing capacity, and trade policy shifts. Validation of key findings was achieved through workshops with subject-matter experts and review of recent case studies that illustrate successful translation of NDDS into clinical and commercial products. This multi-method approach ensures that conclusions are grounded in technical reality, informed by stakeholder perspectives, and applicable to strategic decision-making in both development and commercialization contexts.

Synthesis of how technological progress, clinical strategy, and operational readiness jointly determine which delivery innovations will meaningfully transform oncology care moving forward

The current trajectory of next-generation drug delivery systems in oncology points toward an era in which delivery innovation is integral to therapeutic efficacy, patient experience, and commercial differentiation. Engineering advances across dendrimers, lipid-based carriers, exosome-inspired constructs, and implantable devices enable precise spatial and temporal control of drug exposure, while the incorporation of nucleic acid therapeutics and targeted biologics broadens the range of addressable molecular pathways. These technical advances are matched by shifts in clinical development paradigms that emphasize biomarker-driven patient selection and combination strategies integrating immunomodulation and localized delivery.

However, realizing the full potential of NDDS requires deliberate attention to manufacturing scale-up, robust characterization methods, and regulatory engagement early in development. Policy shifts and trade dynamics have underscored the need for resilient supply chains and flexible sourcing strategies. Organizations that combine disciplined CMC practices with strategic partnerships, adaptive clinical designs, and patient-centered delivery models will be best positioned to translate platform strengths into tangible clinical and commercial outcomes. The field is poised for continued innovation, but success will hinge on integrating technical excellence with pragmatic execution across regulatory, manufacturing, and market access domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. NDDS in Cancer Therapy Market, by Product Type

  • 8.1. Dendrimers
  • 8.2. Exosomes
  • 8.3. Lipid Nanocarriers
  • 8.4. Liposomes
  • 8.5. Metallic Nanoparticles
  • 8.6. Micelles
  • 8.7. Nanoemulsions
  • 8.8. Polymeric Nanoparticles

9. NDDS in Cancer Therapy Market, by Drug Type

  • 9.1. Gene Therapy Agents
  • 9.2. Monoclonal Antibodies
  • 9.3. Oligonucleotide Drugs
  • 9.4. SiRNA
  • 9.5. Small-Molecule Chemotherapeutics

10. NDDS in Cancer Therapy Market, by Technology Platform

  • 10.1. Implantable Depot Systems
  • 10.2. Injectable Suspensions
  • 10.3. Microneedle Systems
  • 10.4. Nanotechnology

11. NDDS in Cancer Therapy Market, by Application

  • 11.1. Chemotherapy
  • 11.2. Immunotherapy
  • 11.3. Photodynamic Therapy
  • 11.4. Radiotherapy
  • 11.5. Targeted Therapy

12. NDDS in Cancer Therapy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. NDDS in Cancer Therapy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. NDDS in Cancer Therapy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States NDDS in Cancer Therapy Market

16. China NDDS in Cancer Therapy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. AstraZeneca PLC
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. F. Hoffmann-La Roche Ltd
  • 17.10. Johnson & Johnson
  • 17.11. Merck & Co., Inc.
  • 17.12. Novartis AG
  • 17.13. Pfizer Inc.
  • 17.14. Samyang Holdings Corporation
  • 17.15. Sanofi S.A.
  • 17.16. Teva Pharmaceutical Industries Ltd.
  • 17.17. West Pharmaceutical Services, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NDDS IN CANCER THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NDDS IN CANCER THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPID NANOCARRIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY LIPOSOMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY METALLIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICELLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOEMULSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GENE THERAPY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY OLIGONUCLEOTIDE DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY SMALL-MOLECULE CHEMOTHERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMPLANTABLE DEPOT SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY INJECTABLE SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY MICRONEEDLE SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY NANOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 123. GCC NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 138. G7 NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 143. NATO NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL NDDS IN CANCER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA NDDS IN CANCER THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA NDDS IN CANCER THERAPY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)